Vivos Therapeutics Stock Analysis

Vivos Stock Analysis Notes

About 14.0% of the company outstanding shares are owned by institutional investors. The book value of Vivos Therapeutics was at this time reported as 0.22. The company recorded a loss per share of 4.99. Vivos Therapeutics had not issued any dividends in recent years. The entity had 1:25 split on the 27th of October 2023. Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea , and snoring in adults. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado. Vivos Therapeutics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 165 people. For more information please call the company at 844 672 4357 or visit https://www.vivos.com.

Vivos Therapeutics Investment Alerts

Vivos Therapeutics Upcoming and Recent Events

Vivos Largest EPS Surprises

View All Earnings Estimates

Vivos Therapeutics Environmental, Social, and Governance (ESG) Scores

Vivos Therapeutics Thematic Classifications

Vivos Stock Institutional Investors

Note, although Vivos Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Vivos Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 17.02 M.

Vivos Profitablity

The company has Profit Margin (PM) of (0.86) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.48) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.48.

Management Efficiency

Vivos Therapeutics has return on total asset (ROA) of (0.57) % which means that it has lost $0.57 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.8496) %, meaning that it created substantial loss on money invested by shareholders. Vivos Therapeutics' management efficiency ratios could be used to measure how well Vivos Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.91 in 2024. Return On Capital Employed is likely to gain to -4.78 in 2024. At this time, Vivos Therapeutics' Total Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 27 M in 2024, whereas Total Current Assets are likely to drop slightly above 2.3 M in 2024.

Technical Drivers

As of the 28th of November, Vivos Therapeutics has the Coefficient Of Variation of 1398.74, semi deviation of 5.6, and Risk Adjusted Performance of 0.0637. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Vivos Therapeutics, as well as the relationship between them. Please validate Vivos Therapeutics standard deviation, as well as the relationship between the value at risk and kurtosis to decide if Vivos Therapeutics is priced more or less accurately, providing market reflects its prevalent price of 3.4 per share. Given that Vivos Therapeutics has jensen alpha of 0.4829, we advise you to double-check Vivos Therapeutics's current market performance to make sure the company can sustain itself at a future point.

Vivos Therapeutics Price Movement Analysis

Vivos Therapeutics Insider Trading Activities

Vivos Therapeutics Outstanding Bonds

Vivos Therapeutics Predictive Daily Indicators

Vivos Therapeutics Corporate Filings

Vivos Therapeutics Forecast Models

Vivos Therapeutics' time-series forecasting models are one of many Vivos Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Vivos Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Vivos Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Vivos shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Vivos Therapeutics. By using and applying Vivos Stock analysis, traders can create a robust methodology for identifying Vivos entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Vivos analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Vivos analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Vivos Therapeutics stock analysis indicators help investors evaluate how Vivos Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Vivos Therapeutics shares will generate the highest return on investment. By understating and applying Vivos Therapeutics stock analysis, traders can identify Vivos Therapeutics position entry and exit signals to maximize returns.

When running Vivos Therapeutics' price analysis, check to measure Vivos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vivos Therapeutics is operating at the current time. Most of Vivos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vivos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vivos Therapeutics' price. Additionally, you may evaluate how the addition of Vivos Therapeutics to your portfolios can decrease your overall portfolio volatility.